Vascular Endothelial Growth Factor (e.g., Vegf-a, Vegf-b, Etc.) Or Derivative Patents (Class 514/8.1)
-
Publication number: 20140377330Abstract: The invention relates to a bioactive hydrogel as a hybrid material of heparin and star-branched polyethylene glycol with functionalized end groups, wherein the heparin is bound directly by reaction of the carboxyl groups activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimides/N-hydroxysulfosuccinimide (EDC/s-NHS) with the terminal amino groups of the polyethylene glycol covalently by amide bonds.Type: ApplicationFiled: September 8, 2014Publication date: December 25, 2014Inventors: Carsten Werner, Uwe Freudenberg, Dorit Meinhold, Marie-Francoise Gouzy, Petra Welzel
-
Publication number: 20140379094Abstract: The claimed invention provides a fusion polypeptide comprising a fibrous protein domain and a mineralization domain. The fusion is used to form an organic-inorganic composite. These organic-inorganic composites can be constructed from the nano- to the macro-scale depending on the size of the fibrous protein fusion domain used. In one embodiment, the composites can also be loaded with other compounds (e.g., dyes, drugs, enzymes) depending on the goal for the materials, to further enhance function. This can be achieved during assembly of the material or during the mineralization step in materials formation.Type: ApplicationFiled: May 16, 2014Publication date: December 25, 2014Applicants: TRUSTEES OF TUFTS COLLEGE, UNITED STATES OF AMERICAN AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE AFM, UNIVERSITY OF ILLINOIS AT CHICAGOInventors: David L. Kaplan, Jia Huang, Cheryl Wong Po Foo, Rajesh Naik, Anne George
-
Publication number: 20140370094Abstract: The inventions provided herein relate to silk-based scaffolds and methods of producing the same, which can be used for a range of tissue engineering applications. The fabrication methods described herein provide a versatile platform to incorporate hollow conduits (e.g., for nutrient/oxygen delivery) through three-dimensional silk-based scaffolds that have tunable bulk properties (e.g., but not limited to, porosity, mechanical, degradation rate) and allow endothelialization and/or cell compartmentalization, for engineering a variety of complex tissue equivalents.Type: ApplicationFiled: November 8, 2012Publication date: December 18, 2014Inventors: Lindsay Wray, Jelena Rnjak-Kovacina, David L. Kaplan
-
Patent number: 8906648Abstract: A process for recovering and purifying refolded heparin binding proteins produced in heterologous host cells includes the step of incubation of the solubilized protein with a polyanionic species such as dextran sulfate.Type: GrantFiled: March 26, 2013Date of Patent: December 9, 2014Assignee: Genentech, Inc.Inventors: Michelle D. Butler, Jeffrey L. Cleland, David W. Kahn, Shelly Pizarro, Charles H. Schmelzer, Marjorie E. Winkler
-
Publication number: 20140356286Abstract: Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.Type: ApplicationFiled: April 21, 2014Publication date: December 4, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jennifer R. Cochran, Adam Silverman, Douglas Jones, Niv Papo
-
Publication number: 20140349929Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: ApplicationFiled: March 28, 2014Publication date: November 27, 2014Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Ray CAMPHAUSEN, Eric FURFINE, Irvith M. CARVAJAL, H. Nicholas MARSH, Marco GOTTARDIS, Joan CARBONI, Ricardo ATTAR
-
Publication number: 20140341814Abstract: Compounds of general formula (1): X1Y1X2Y2X3Y3X4Y4Y5X5X6Y6X7Y7X8X9X10 wherein X1-X10 are any natural or unnatural amino acids and Y1 is Gln; Y2 is Met or Leu; Y3 is He; Y4 is Pro or Ser; Y5 is His or Gly; Y6 is Gln or Pro; Y7 is He or Tyr or their homolog or ortolog are described; these compounds are able to bind to the VEGF receptors and to modulate the angiogenesis mediated by the VEG.Type: ApplicationFiled: April 22, 2014Publication date: November 20, 2014Inventors: Luca Domenico D'Andrea, Carlo Pedone, Maria Caterina Turco
-
Patent number: 8889620Abstract: The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.Type: GrantFiled: February 3, 2012Date of Patent: November 18, 2014Assignee: Children's Medical Center CorporationInventors: Michael Klagsbrun, Shay Soker
-
Publication number: 20140335145Abstract: The invention provides products of manufacture, e.g., biomaterials and implants, for cartilage maintenance and/or formation in-vivo, in-vitro, and ex-vivo, using nanotechnology, e.g., using nanotube, nanowire, nanopillar and/or nanodepots configured on surface structures of the products of manufacture.Type: ApplicationFiled: July 27, 2014Publication date: November 13, 2014Inventors: Sungho JIN, Seunghan OH, Karla BRAMMER
-
Patent number: 8883724Abstract: Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.Type: GrantFiled: November 4, 2009Date of Patent: November 11, 2014Assignee: Centro de Ingenieria Genética y BiotecnologiaInventors: Mónica Bequet Romero, Boris Ernesto Acevedo Castro, Jorge Victor Gavilondo Cowley, Luis Enrique Fernández Molina, Omar Lopez Ocejo, Ricardo de la Caridad Silva Rodriguez, Alexis Musachio Lasa, Ernesto Galban Rodriguez, Dania Marcia Vásquez Blomquist
-
Patent number: 8883184Abstract: Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament.Type: GrantFiled: January 20, 2009Date of Patent: November 11, 2014Assignee: Pioneer Surgical Technology, Inc.Inventors: Ronald Stewart Hill, Richard Chris Klann, Francis V. Lamberti
-
Patent number: 8883738Abstract: The present invention relates to the use of peptide compounds for the prevention and/or treatment of ophthalmic diseases. In particular, the present invention relates to a peptide compound comprising an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 2 (KEQWFGNRWHEGYR) or of SEQ ID NO: 1 (KEKWFENEWQGKNP), or a functionally active derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatmend of an ophthalmic disease in an individual. While SEQ ID NO: 2 is a part of the human CD44v6, SEQ ID NO: 1 is a part of the rat CD44v6.Type: GrantFiled: December 13, 2012Date of Patent: November 11, 2014Assignee: Karisruher Insitut für TechnologieInventors: Alexandra Matzke, Helmut Ponta, Véronique Orian-Rousseau, Martina Tremmel
-
Publication number: 20140322292Abstract: Methods of promoting bone healing or regeneration by locally administering insulin mimetic agents to patients in need thereof and new uses of insulin-mimetic compounds for accelerating bone-healing processes are disclosed. Bone injury treatment and void filler devices, products and kit suitable for local administration of insulin-mimetic agents or compositions thereof to patients in need of such treatment are also disclosed.Type: ApplicationFiled: November 29, 2012Publication date: October 30, 2014Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Sheldon S. Lin, David N. Paglia, James P. O'Connor, Joseph Benevenia, Aaron Wey, Sangeeta Subramanian, John D. Koerner
-
Publication number: 20140315804Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.Type: ApplicationFiled: March 13, 2014Publication date: October 23, 2014Applicant: GENZYME CORPORATIONInventors: Peter PECHAN, Jeffery ARDINGER, Hillard RUBIN, Samuel WADSWORTH, Abraham SCARIA
-
Publication number: 20140315803Abstract: A method for promoting hair growth in a human in need of promoting hair growth. The method includes preparing a composition comprising a therapeutically effective amount of at least three of: a Bone Morphogenetic Protein, Transforming Growth Factor Beta, Platelet Derived Growth Factor, Insulin-like Growth Factor, Basic Fibroblastic Growth Factor and Vascular Endothelial Growth Factor; and administering the composition to the human.Type: ApplicationFiled: April 17, 2013Publication date: October 23, 2014Inventor: Mark Laney
-
Publication number: 20140308264Abstract: Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders.Type: ApplicationFiled: June 23, 2014Publication date: October 16, 2014Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
-
Patent number: 8859706Abstract: The invention relates to a bioactive hydrogel as a hybrid material of heparin and star-branched polyethylene glycol with functionalized end groups, wherein the heparin is bound directly by reaction of the carboxyl groups activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimides/N-hydroxysulfosuccinimide (EDC/s-NHS) with the terminal amino groups of the polyethylene glycol covalently by amide bonds.Type: GrantFiled: November 28, 2008Date of Patent: October 14, 2014Assignee: Zetascience GmbHInventors: Carsten Werner, Uwe Freudenberg, Dorit Meinhold, Marie-Francoise Gouzy, Petra Welzel
-
Publication number: 20140302111Abstract: Provided is a method for regenerating dental tissue, which can include contacting a scaffold containing Wnt3a and BMP-7, and optionally VEGF, bFGF, or NGF, with a dental tissue so as to promote odontoblastic differentiation of a progenitor cell, promote progenitor cell migration into the dental tissue, or regenerate the dental tissue. Also provided is a composition for regeneration of dental tissue, which can include a scaffold and Wnt3a and BMP-7, and optionally VEGF, bFGF, or NGF.Type: ApplicationFiled: March 21, 2014Publication date: October 9, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventors: Jeremy J. Mao, Ying Zheng, Guoming Sun, Songlin Wang
-
Publication number: 20140294960Abstract: Implantable modular hydrogels to aid in salivary gland restoration and associated methods are provided. In one embodiment, the present disclosure provides for a hydrogel network comprising: a hyaluronic acid macromer crosslinked with a multiblock copolymer.Type: ApplicationFiled: June 16, 2014Publication date: October 2, 2014Inventors: Robert L. Witt, Xinqiao Jia, Swati Pradham Bhatt, Mary C. Farach-Carson, Daniel A. Harrington
-
Patent number: 8840883Abstract: Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. Addition of a non-protein-type metal chelator provided further improvement in the action of the bio-functional activity of T3. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements.Type: GrantFiled: November 9, 2012Date of Patent: September 23, 2014Assignee: Naidu LPInventors: A. Satyanarayan Naidu, A. G. Sreus Naidu, A. G. Tezus Naidu
-
Publication number: 20140271779Abstract: Synthetic, bioactive ultra-porous bone graft materials having an engineered porosity, and implants formed from such materials are provided. In particular, these implants comprise bioactive glass and incorporate allograft material for osteoinduction. The implants are suitable for bone tissue regeneration and/or repair.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: PROSIDYAN, INC.Inventors: Charanpreet S. BAGGA, Steve B. JUNG, Hyun W. BAE
-
Publication number: 20140271589Abstract: Methods of stimulating collagen production, including stimulation of chondrocyte production, at the site of a defect. Methods include administering to the site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: BIOMET BIOLOGICS, LLCInventors: Andrea MATUSKA, Krista O'SHAUGHNESSEY, Jennifer E. WOODELL-MAY
-
Publication number: 20140256630Abstract: The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.Type: ApplicationFiled: January 7, 2014Publication date: September 11, 2014Applicant: Indi Molecular, Inc.Inventors: Suresh Mark PITRAM, Heather Dawn AGNEW, Tsun Yin LAI, Rosemary Dyane ROHDE, Paul Edward Kearney, Scott LAW, Kenneth Charles FANG
-
Patent number: 8828946Abstract: The present invention relates to pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated.Type: GrantFiled: December 10, 2010Date of Patent: September 9, 2014Assignee: Orthogen AGInventors: Peter Wehling, Julio Reinecke
-
Patent number: 8822415Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: July 19, 2013Date of Patent: September 2, 2014Assignee: Stemnion, Inc.Inventors: Catherine J. Trumpower, George L. Sing, Linda O. Palladino
-
Publication number: 20140227362Abstract: The present invention is directed to methods of manufacturing bioactive gels from ECM material, i.e., gels which retain bioactivity, and can serve as scaffolds for preclinical and clinical tissue engineering and regenerative medicine approaches to tissue reconstruction. The manufacturing methods take advantage of a new recognition that bioactive gels from ECM material can be created by digesting particularized ECM material in an alkaline environment and neutralizing to provide bioactive gels.Type: ApplicationFiled: February 7, 2014Publication date: August 14, 2014Inventors: Kimberly A. Kentner, Katherine A. Stuart, Abram D. Janis
-
Patent number: 8802107Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.Type: GrantFiled: June 11, 2013Date of Patent: August 12, 2014Assignee: Regeneron Pharmaceuticals, IncInventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
-
Publication number: 20140219953Abstract: Described herein is a cell tissue gel cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent.Type: ApplicationFiled: January 2, 2014Publication date: August 7, 2014Applicants: Excel Med, LLC, National Cheng Kung UniversityInventor: Lynn L.H. Huang
-
Patent number: 8778869Abstract: A system for growing tissue based upon layers of an inorganic extracellular matrix, wherein each layer of the inorganic matrix is designed to dissolve at a separate rate and result in sequential growth factor delivery upon its dissolution.Type: GrantFiled: June 9, 2010Date of Patent: July 15, 2014Assignee: Wisconsin Alumni Research FoundationInventors: William L. Murphy, Mark D. Markel, Ben K. Graf, Yan Lu, Jae Sung Lee
-
Patent number: 8772236Abstract: The invention relates to the fields of protein chemistry, biology and medicine. More specifically, it relates to the design and preparation of proteinmimics of members of the cystine-knot growth factor superfamily. Further, the invention relates to the use of these proteinmimics as a medicament or prophylactic agent. The invention provides proteinmimics of members of the cystine-knot growth factor superfamily, preferably for use in immunogenic and/or therapeutic compositions.Type: GrantFiled: February 5, 2010Date of Patent: July 8, 2014Assignees: Pepscan Systems B.V., Universiteit Maastricht, Academisch Ziekenhuis MaastrichtInventors: Peter Timmerman, Wouter C. Puijk, Tilman M. Hackeng, Arjan W. Griffioen
-
Publication number: 20140179601Abstract: There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising a first isolated nucleic acid molecule that encodes a FGF-9 polypeptide and optionally one or more isolated nucleic acid molecule that encodes another angiogenic polypeptide. There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising administering an effective amount of a composition comprising an isolated FGF-9 polypeptide and one or more other angiogenic polypeptides. The compositions provided herein may be useful for controlling angiogenesis and/or vasculogenesis.Type: ApplicationFiled: November 28, 2013Publication date: June 26, 2014Applicant: UNIVERSITY OF WESTERN ONTARIOInventors: Geoffrey J. Pickering, Zengxuan Nong, Matthew Frontini
-
Patent number: 8759285Abstract: Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders.Type: GrantFiled: October 6, 2006Date of Patent: June 24, 2014Assignee: Trophogen, Inc.Inventors: Mariusz W. Szkudlinski, Bruce D. Weintraub
-
Patent number: 8759286Abstract: Described herein are pharmaceutical compositions comprising a VEGF-D polypeptide.Type: GrantFiled: April 19, 2013Date of Patent: June 24, 2014Assignee: Vegenics Pty LimitedInventors: Marc G. Achen, Stephen A. Stacker, Kari Alitalo, Andrew F. Wilks
-
Patent number: 8741850Abstract: Compounds of general formula (1): X1Y1X2Y2X3Y3X4Y4Y5X5X6Y6X7Y7X8X9X10 wherein X1-X10 are any natural or unnatural amino acids and Y1 is Gln; Y2 is Met or Leu; Y3 is He; Y4 is Pro or Ser; Y5 is His or Gly; Y6 is Gln or Pro; Y7 is He or Tyr or their homolog or ortolog are described; these compounds are able to bind to the VEGF receptors and to modulate the angiogenesis mediated by the VEG.Type: GrantFiled: July 23, 2010Date of Patent: June 3, 2014Assignee: Advanced Accelerator Applications S.A.Inventors: Luca Domenico D'Andrea, Carlo Pedone, Maria Caterina Turco
-
Patent number: 8741839Abstract: Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.Type: GrantFiled: January 18, 2010Date of Patent: June 3, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jennifer R. Cochran, Adam Silverman, Douglas Jones, Niv Papo
-
Publication number: 20140148386Abstract: Disclosed is a method for the prevention or treatment of vascular leakage-induced diseases and diabetic retinopathy, using C-peptide. Found to prevent extravascular leakage by inhibiting VEGF-induced disassembly of VE-cadherin, C-peptide can be applied to the prevention or treatment of various diabetic complications accompanied by vascular leakage.Type: ApplicationFiled: August 6, 2013Publication date: May 29, 2014Applicants: AMOGREENTECH CO., LTD., KANGWON NATIONAL UNIVERSITY UNIVERSITY- INDUSTRY COOPERATION FOUNDATIONInventors: Kwon-Soo Ha, Young-Cheol Lim
-
Publication number: 20140135264Abstract: A pharmaceutical composition includes a synthetic peptide consisting of about 10 to about 50 amino acids and having an amino acid sequence substantially homologous to consecutive amino acids of a portion of the cytoplasmic domain of at least one of ?v?3 integrin or VEGFR2 that includes a tyrosine residue, the amino acid sequence of the peptide including a phosphorylated tyrosine residue or a ?-carboxyglutamic acid residue that is substituted for a corresponding tyrosine residue of the portion of the cytoplasmic domain of ?v?3 integrin or VEGFR2.Type: ApplicationFiled: December 14, 2012Publication date: May 15, 2014Applicant: THE CLEVELAND CLINIC FOUNDATIONInventors: Tatiana Byzova, Ganapati Bhat, Weiyi Feng
-
Patent number: 8722075Abstract: A method for promoting bone formation is provided. More specifically, a method for promoting bone formation by promoting osteoclast formation is provided. In one embodiment, an implant comprising an implantable material and an osteoclast stimulating substance is provided.Type: GrantFiled: October 26, 2009Date of Patent: May 13, 2014Assignee: Warsaw Orthopedic, Inc.Inventors: Lawrence A. Shimp, Keyvan Behnam, Guobao Wei, Abdulhafez A. Selim
-
Publication number: 20140127187Abstract: Disclosed are a novel therapeutic agent and a novel treatment method for cancer. Specifically disclosed are: a targeting agent for a cell selected from the group consisting of a cancer cell and a cancer-associated fibroblast, which comprises a retinoid; a substance delivery carrier for the cell, which comprises the targeting agent; an anti-cancer composition utilizing the targeting agent or the carrier; an anti cancer-associated fibroblast composition; and a method for treatment of cancer.Type: ApplicationFiled: January 8, 2014Publication date: May 8, 2014Applicant: Nitto Denko CorporationInventors: Yoshiro Niitsu, Rishu Takimoto
-
Publication number: 20140121160Abstract: An agonist of the VEGF receptor is useful in the treatment of a disease associated with retarded fetal growth, such as intra-uterine growth retardation. The VEGF against may be a VEGF peptide or a gene construct encoding or expressing such a PI-peptide.Type: ApplicationFiled: October 29, 2012Publication date: May 1, 2014Inventors: John Francis MARTIN, Charles Henry RODECK
-
Patent number: 8710004Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.Type: GrantFiled: March 23, 2012Date of Patent: April 29, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Daniel Dix, Kelly Frye, Susan Kautz
-
Patent number: 8710180Abstract: The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.Type: GrantFiled: August 31, 2012Date of Patent: April 29, 2014Assignee: Indi Molecular, Inc.Inventors: Suresh Mark Pitram, Heather Dawn Agnew, Tsun Yin Lai, Rosemary Dyane Rohde, Paul Edward Kearney
-
Publication number: 20140105856Abstract: System and methods for isolation of collagen and other fibrous tissue from adipose tissue are described herein. The method of the present invention isolates the collagen from adipose tissue by sonication. The tissue to be sonicated is placed in a container or a flow cell transparent to ultrasound waves. After sonication the sonicated material is filtered out through the bottom of the flow cell and the sonicated collagen is trapped in the filter, which may be taken for further processing. The isolated collagen can then be combined with a suitable carrier for re-injection to correct various tissue defects such as wrinkles, to form a carrier for the stem cells, a filler, and matrix for new collagen production by injecting into the desired area of the host.Type: ApplicationFiled: June 22, 2012Publication date: April 17, 2014Inventor: Stephen Schendel
-
Publication number: 20140105960Abstract: Provided herein are hydrogels and hydrogel-forming compositions that are useful for, among others, tissue regeneration in vivo. Methods for generating such hydrogels, for example, from such hydrogel-forming compositions are also provided herein. Therapeutic methods employing hydrogels and hydrogel-forming composition, for example, for restoration of tissue perfusion in the context of acute ischemia, are also provided. The disclosure also describes kits comprising components useful for generating hydrogels as described herein.Type: ApplicationFiled: October 9, 2013Publication date: April 17, 2014Applicants: Children's Medical Center Corporation, Massachusetts Institute of TechnologyInventors: JANETA ZOLDAN, Robert S. Langer, Daniel S. Kohane, Daniel Griffith Anderson, Akihiko Kusanagi, Hila Epstein-Barash, Beata Chertok
-
Patent number: 8697107Abstract: A flowable biomedical implant for application to a bone defect to promote bone growth is provided. The flowable biomedical implant comprises a carrier matrix including a biodegradable polysaccharide and ceramic material. An impermeable membrane can be integrally formed at the surface of the carrier matrix by applying a crosslinking agent to the biodegradable polysaccharide mixed with ceramic materials.Type: GrantFiled: April 27, 2012Date of Patent: April 15, 2014Assignee: Warsaw Orthopedic, Inc.Inventors: Susan J. Drapeau, Daniel A. Shimko
-
Publication number: 20140100159Abstract: The subject invention relates to methods for improving a subject's vasculature to normalize maternal hemodynamics, particularly in subjects attempting to conceive via assisted reproductive technologies, and comprises increasing relaxin levels in a subject or increasing any one or more of: relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, or relaxin receptor activity.Type: ApplicationFiled: October 9, 2013Publication date: April 10, 2014Applicant: University Of Florida Research Foundation, Inc.Inventor: KIRK P. CONRAD
-
Publication number: 20140100160Abstract: The present invention relates to a pharmaceutical composition for inhibiting angiogenesis comprising an isolated peptide comprising the heparin-binding domain of insulin-like growth factor-binding protein-5 (IGFBP-5), a method for inhibiting angiogenesis using the peptide, a pharmaceutical composition for the prevention or treatment of cancer comprising the peptide, a method for treating cancer using the peptide, a novel angiogenesis-inhibiting peptide derived from heparin-binding domain of IGFBP-5, a polynucleotide encoding the peptide, an expression vector comprising the polynucleotide and a transformant comprising the vector.Type: ApplicationFiled: October 9, 2013Publication date: April 10, 2014Applicant: Research & Business Foundation Sungkyunkwan UniversityInventor: Jae Ryoung HWANG
-
Publication number: 20140093520Abstract: The present invention relates to methods for modulating, i.e. increasing or decreasing, the length and/or the complexity of the dendrites of a neuronal cell by influencing the amount of vascular endothelial growth factor D (VEGFD)-related signaling. The present invention further relates to methods for treating age- and/or disease-related cognitive dysfunctions, or for impairing the memory of a subject. Finally, the present invention relates to recombinant VEGFD (rVEGFD) for use in the treatment of age- and/or disease-related cognitive dysfunctions.Type: ApplicationFiled: June 1, 2012Publication date: April 3, 2014Applicant: UNIVERSITAT HEIDELBERGInventors: Hilmar Bading, Daniela Mauceri, Chistian Klein
-
Publication number: 20140086974Abstract: Biodegradable drug delivery systems, such as extruded implants, for the sustained delivery of a protein to an ocular region of the eye or intraarticular region in the body are described. The drug delivery systems may be used to treat a variety of ocular and medical conditions, including macular degeneration. Methods for using and making the drug delivery systems are also described. The drug delivery systems can be in the form of extruded filaments configured for placement in an ocular region such as the vitreous body or anterior chamber of the eye.Type: ApplicationFiled: September 26, 2013Publication date: March 27, 2014Inventors: Cindy W. Wu, Michael R. Robinson, James A. Burke, Patrick M. Hughes
-
Publication number: 20140088502Abstract: An injector system for delivery of a pharmacological agent to biological tissue having a plurality of needles arranged in an array, a plurality of reservoirs configured to receive a pharmacological composition therein, the reservoirs being in fluid communication with a respective one of the plurality of needles, a pneumatic pressure source, a pneumatic drive system that is configured to induce a first discharge of the pharmacological composition out of the reservoirs and needles in a plurality of delivery modes, agent delivery volume control means for controlling volume of the pharmacological composition discharged from the needles, and a control system having actuation control means for controlling said pneumatic drive system. The control system is programmed to control the delivery modes.Type: ApplicationFiled: September 19, 2013Publication date: March 27, 2014Inventors: Robert G. Matheny, Bret Herscher, Michael Perry